VOLGA (LBA2, #ESMO26): cisplatin-ineligible/refusing MIBC — neoadjuvant enfortumab vedotin + peri-op durvalumab vs control.

Circulating figures (EV+durva arm): 2-yr EFS 64% vs 45% (HR 0.51); 2-yr OS 78% vs 69% (HR 0.58); pCR ~45% vs ~10%.

Tremelimumab arm: EFS HR ~0.61, OS NS at interim. Absolute rates unverified — confirm at PS I (Powles).

@tompowles1